Adjuvant interferon in high-risk melanoma: the AIM HIGH Study–United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma - Hancock,B.W.; Wheatley,K.; Harris,S. (J Clin Oncol, 2004)